Fosaprepitant

Fosaprepitant (INN; trade names Emend for Injection, Ivemend) is an anti-emetic drug, administered intravenously. It is a prodrug of aprepitant.

It was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008. and by the European Medicines Agency (EMA) on January 11 of the same year.